pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,108 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1801Endpoints1403Fierce Biotech721BioSpace712BioPharma Dive530raps239onclive165fda recalls
therapy area
allOncology12439Rare Disease3241Immunology2910Cardiology2788Hematology2198Pulmonology2154Vaccines
  • CSL appoints former ViiV and GSK veteran Deborah Waterhouse as new CEO
    CSL announced that Deborah Waterhouse will become its chief executive. The appointment follows her departure from GSK, where she spent three decades. Waterhouse most recently led ViiV Healthcare,…
    Endpoints · 22d agoPositive↗ source
  • Alcon buys Neurotech for $550 million upfront
    Alcon, the Swiss eye‑care company, announced it has completed the acquisition of Neurotech Pharmaceuticals. The transaction includes an upfront cash payment of $550 million, with the possibility o…
    Endpoints · 22d agoDealNeutral↗ source
← prev
page 19 of 125
next →
114
fda medwatch112
globenewswire health73
fda press59
1818
Psychiatry & CNS1212
Ophthalmology1074
Endocrinology & Metabolism782
Pain780
Nephrology764
  • Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filing
    Roivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies. The trials, which evaluated the drug in separate autoimmune indications, showed statistically signi…
    Endpoints · 22d agoPositive readoutPositive↗ source
  • Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting shares
    Arcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…
    BioPharma Dive · 22d agoPositive readoutPositive↗ source
  • Lilly advances retatrutide toward sleep-apnea market
    Eli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…
    Endpoints · 23d agoPositive↗ source
  • Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totals
    Crossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…
    BioSpace · 23d agoDealNeutral↗ source
  • China biotech RiboX reports first human data for circular RNA therapies
    China biotech company RiboX has disclosed its initial human data on circular RNA therapeutics, marking the first clinical readout for this emerging platform. The study represents a milestone for t…
    Endpoints · 22d agoNeutral↗ source
  • Samsung Biologics union vows appeal after court blocks planned strike
    A Seoul court granted Samsung Biologics an order that prevents its labor union from holding a strike that had been scheduled for the company's bio-manufacturing campus. The union, representing con…
    Endpoints · 22d agoNegative↗ source
  • FDA device officials prioritize hiring after layoffs, express optimism for upcoming MDUFA VI agreement
    Top officials from the FDA's Center for Devices and Radiological Health spoke at a town‑hall session during The MedTech Conference. They said the agency is concentrating on rebuilding staff after a…
    raps · 23d agoRegulatoryPositive↗ source
  • Endpoints AI Day highlights agents, AI slop and biosecurity gaps in pharma
    Endpoints News held its third AI Day, an event dedicated to exploring how artificial intelligence can be applied across drug discovery and development. Speakers, including Nathan Frey of Anthropic…
    Endpoints · 22d agoNeutral↗ source
  • Pharma companies push FDA for risk-based flexibility in container-closure testing guidance
    Major pharma firms have written to the FDA urging a shift in its current guidance on testing container-closure systems for drug and biologic products. They argue that a risk-based, flexible approa…
    raps · 23d agoRegulatoryNeutral↗ source
  • Eight biopharma companies posting dozens of remote job openings
    BioSpace compiled a list of eight biopharma firms currently advertising remote positions for life‑science professionals. The companies together have roughly 300 openings, ranging from strategic ac…
    BioSpace · 22d agoNeutral↗ source
  • Companies price the role, not the employee, says executive coach on compensation expectations
    Executive coach Angela Justice argues that firms usually set pay based on the value of the job itself rather than the individual who fills it. She says this distinction is often clear in theory but…
    BioSpace · 23d agoNegative↗ source
  • FDA approves Hibsago, first antisense therapy for chronic hepatitis B
    The U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…
    fda press · 23d agoApprovalPositive↗ source
  • Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readout
    Genmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…
    BioSpace · 24d agoNegative↗ source
  • Rapport Therapeutics' epilepsy drug RAP-219 meets primary endpoint in bipolar mania Phase II trial
    Rapport Therapeutics reported that its experimental pill RAP-219, originally developed for epilepsy, was tested in a mid‑stage study of adults with bipolar mania. The trial enrolled roughly 250 par…
    BioPharma Dive · 23d agoPositive readoutPositive↗ source
  • ICER reports two-thirds of new drugs launched 2022-2025 priced well above cost-effectiveness thresholds
    ICER’s latest analysis of launch prices for new prescription medicines shows a sharp rise in net costs between 2022 and 2025. After adjusting for inflation, the median price climbed from $190,000 i…
    BioPharma Dive · 23d agoNegative↗ source
  • Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trial
    Rapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…
    BioSpace · 23d agoPositive readoutPositive↗ source
  • Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in years
    Endpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downt…
    Endpoints · 23d agoPositive↗ source
  • Lilly commits up to $1.1 billion to Hong Kong biotech METiS TechBio's AI-driven lipid nanoparticle platform
    Lilly announced a partnership with Hong Kong‑listed METiS TechBio, providing an upfront payment in the low double‑digit‑million‑dollar range and making the company eligible for up to $1.1 billion i…
    BioSpace · 23d agoDealPositive↗ source
  • Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchise
    Alnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…
    BioSpace · 24d agoEarningsNegative↗ source
  • AstraZeneca teams with Oracle on AI-driven clinical trials as FDA clears Haemonetics vascular closure system
    AstraZeneca announced a collaboration with technology firm Oracle to incorporate artificial intelligence into its clinical trial processes. The partnership aims to use Oracle's cloud and data analy…
    raps · 24d agoApprovalPositive↗ source
  • ICER report finds median launch drug prices jumped 24% between 2022 and 2025
    The Institute for Clinical and Economic Review released a new analysis showing that the median list price of newly launched drugs increased by 24% from 2022 to 2025. The report also notes that net…
    Endpoints · 23d agoNegative↗ source
  • FDA approves first generic weekly hormone patch for menopausal women
    The U.S. Food and Drug Administration has granted approval for a generic version of a once‑weekly transdermal hormone patch that combines estradiol and levonorgestrel. The product matches the brand…
    fda press · 23d agoApprovalPositive↗ source
  • Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopenia
    Pfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood d…
    Endpoints · 23d agoNegative readoutNegative↗ source